We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-7.27%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$391M
AUM Growth
+$66.7M
Cap. Flow
+$96.2M
Cap. Flow %
24.63%
Top 10 Hldgs %
99.75%
Holding
13
New
4
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$63.7M
2
AGN
Allergan plc
AGN
+$46.2M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$25.7M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$11.5M
5
BIIB icon
Biogen
BIIB
+$9.62M

Top Sells

Rank Stock Value
1
ADXS
Advaxis Inc
ADXS
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 86.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$132M 33.75%
413,858
+30,000
+8% +$9.62M
BIVV
2
DELISTED
Bioverativ Inc. Common Stock
BIVV
$62.8M 16.08%
+1,165,000
New +$63.7M
MDCO
3
DELISTED
Medicines Co
MDCO
$52.5M 13.45%
1,922,000
+170,000
+10% +$5.24M
INVA icon
4
Innoviva
INVA
$1.55B
$51.9M 13.3%
3,660,705
+60,000
+2% +$800K
AGN
5
DELISTED
Allergan plc
AGN
$42.1M 10.77%
+257,300
New +$46.2M
IRWD icon
6
Ironwood Pharmaceuticals
IRWD
$696M
$24.7M 6.33%
+1,970,100
New +$25.7M
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$10.6M 2.73%
+182,300
New +$11.5M
ACHN
8
DELISTED
Achillion Pharmaceuticals
ACHN
$7.2M 1.84%
2,500,000
+363,200
+17% +$1.32M
NVLN
9
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$3.2M 0.82%
1,025,000
– –
SEEL
10
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$2.66M 0.68%
13
– –
ABBV icon
11
AbbVie
ABBV
$443B
$967K 0.25%
10,000
– –
ADXS
12
DELISTED
Advaxis Inc
ADXS
– –
-22,612
Closed -$1.42M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sarissa Capital Management held 13 positions worth $391M, up 21% from $324M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $96.2M of net new capital in Q4 2017, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 1,165,000 shares worth $62.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 59% a quarter earlier.

On the sell side, the most notable exit was Advaxis Inc, an estimated $1.42M sold.

  • Sarissa Capital Management's largest Q4 2017 buy was Bioverativ Inc. Common Stock: 1,165,000 shares worth $62.8M.
  • Sarissa Capital Management added most to Biogen in Q4 2017, an estimated $9.62M increase.
  • Sarissa Capital Management fully exited Advaxis Inc in Q4 2017, selling an estimated $1.42M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $391M portfolio in Q4 2017.
  • Sarissa Capital Management opened 4 new positions and closed 2 in Q4 2017.
  • Sarissa Capital Management's portfolio value rose 21% quarter-over-quarter to $391M.

Based on Sarissa Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.